Showing results (201-210 of 242) with videos related to
Sort By:
Pageof 25
Neuro-Oncology|January 15, 2015
A phase II, multicenter trial of rindopepimut (CDX-110) in newly diagnosed glioblastoma: the ACT III studyJames Schuster, Rose K Lai, Lawrence D Recht, et al.Neuro-Oncology|December 15, 2010
Greater chemotherapy-induced lymphopenia enhances tumor-specific immune responses that eliminate EGFRvIII-expressing tumor cells in patients with glioblastomaJohn H Sampson, Kenneth D Aldape, Gary E Archer, et al.The Lancet. Child & Adolescent Health|April 2, 2023
Recombinant polio-rhinovirus immunotherapy for recurrent paediatric high-grade glioma: a phase 1b trialEric M Thompson, Daniel Landi, Michael C Brown, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|February 15, 2003
Phase II trial of temozolomide in patients with progressive low-grade gliomaJennifer A Quinn, David A Reardon, Allan H Friedman, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|June 7, 2005
Dosimetry and radiographic analysis of 131I-labeled anti-tenascin 81C6 murine monoclonal antibody in newly diagnosed patients with malignant gliomas: a phase II studyGamal Akabani, David A Reardon, R Edward Coleman, et al.Neuro-Oncology|May 12, 2004
Phase 1 trial of irinotecan plus BCNU in patients with progressive or recurrent malignant gliomaJennifer A Quinn, David A Reardon, Allan H Friedman, et al.Neuro-Oncology|April 12, 2008
Intracerebral infusion of an EGFR-targeted toxin in recurrent malignant brain tumorsJohn H Sampson, Gamal Akabani, Gerald E Archer, et al.Neuro-Oncology|May 12, 2004
Phase 2 trial of BCNU plus irinotecan in adults with malignant gliomaDavid A Reardon, Jennifer A Quinn, Jeremy N Rich, et al.Nature|March 13, 2015
Tetanus toxoid and CCL3 improve dendritic cell vaccines in mice and glioblastoma patientsDuane A Mitchell, Kristen A Batich, Michael D Gunn, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 14, 2018
T-Cell Exhaustion Signatures Vary with Tumor Type and Are Severe in GlioblastomaKarolina Woroniecka, Pakawat Chongsathidkiet, Kristen Rhodin, et al.Pageof 25